Merck's Keytruda Approval: Fueling Investor Optimism and Analyst Upgrades
Merck's recent FDA approval for Keytruda is boosting investor sentiment and leading to analyst upgrades.
Q32 Bio's 60% Surge: A Game Changer for Alopecia Areata Treatment
Q32 Bio's shares jumped 60% after promising trial results for alopecia areata treatment, with Oppenheimer raising its price target to $40.
Trade with the conviction of the 1%.
Institutional-grade market intelligence delivered before the opening bell.
First Hawaiian Bank's Acquisition of TriCo Bancshares: A Strategic Expansion
First Hawaiian Bank's acquisition of TriCo Bancshares positions it as a leader in the Pacific banking market, promising …
Market Volatility: S&P 500 and Nasdaq Futures React to US-Iran Tensions
Geopolitical tensions impact S&P 500 and Nasdaq futures, sending chip stocks into a tailspin. Traders should stay alert.
VitalHub Expands With Acquisition of Buddy Healthcare: A Strategic Move
VitalHub Corp.'s acquisition of Buddy Healthcare may enhance its digital care coordination capabilities and market posit…
TransDigm's Abandonment of Stellant Systems Deal: Market Reactions
TransDigm's $960 million acquisition of Stellant Systems falls through, impacting investor confidence in the defense sec…
Edgewise Therapeutics' $2.65B Sale: What It Means for Biotech Investors
Analyzing the $2.65 billion sale of sevasemten by Edgewise Therapeutics and its implications for investors.
Q32 Bio's 60% Surge: Implications for Investors in Biotech
Q32 Bio's remarkable 60% surge following positive clinical trial results raises significant questions for biotech invest…
T3 Defense's Acquisition of Project35: A Strategic Move in the Drone Market
T3 Defense strengthens its foothold in the drone sector with a 60% stake in Project35, signaling a pivotal shift in defe…
Baker Hughes Secures EU Approval: What It Means for Energy Investors
Baker Hughes gains EU approval for the Chart Industries acquisition, signaling potential shifts in the energy technology…
BridgeBio Pharma's Stock Surge: An Investor's Guide to the Competitive Implications
BridgeBio Pharma's stock surged 16% after AstraZeneca and Ionis failed a drug trial, reshaping the competitive landscape…